RxDoctor Payments Data

Marisa Brumley, APRN

Family · Conroe, TXNPI 1306295332

Payments from drug & device makers

$8,690in general payments, 2019–2025

Across 340 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • MML US, Inc.$2K
  • AbbVie$1K
  • Boston Scientific$379
  • Collegium Pharmaceutical, Inc.$309
  • Pacira Therapeutics, Inc.$232
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$1,52218%
  • Food & beverage$7,16882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,690 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$87,491
Medicare patients
191
Services billed
1,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate92$35,573
RelistorMethylnaltrexone Bromide13$28,888
UbrelvyUbrogepant11$17,277
Gabapentin179$2,018
Naloxone Hcl11$662
Cyclobenzaprine Hcl58$545
Tizanidine Hcl49$482
Pregabalin33$452
Methocarbamol35$398
Duloxetine Hcl18$362
Mupirocin41$318
Baclofen15$213
Cephalexin11$177
Ondansetron OdtOndansetron14$144
Methylprednisolone11$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$188$28,88813 claims
AbbVieUbrelvy$1,012$17,27711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →